ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.

TAK Takeda Pharmaceutical Company Ltd

13,10
0,02 (0,15%)
15 Juin 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Takeda Pharmaceutical Company Ltd TAK NYSE Certificat de dépôt
  Variation Action Variation Action% Cours Dernier Dernier échange
0,02 0,15% 13,10 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
13,07 13,03 13,12 13,10 13,08
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
14/6/202414:00BWTakeda Signs Option Agreement with Ascentage Pharma to Enter..
11/6/202414:00BWTakeda Announces Partnership Expansion with Partners In..
03/6/202412:45BWTakeda’s TAK-861 Phase 2b Late-Breaking Data Presentations..
01/6/202414:00BWTakeda and Pfizer Announce Four-Year Results from Positive..
31/5/202415:57BWTakeda Receives Positive CHMP Opinion for Recombinant..
21/5/202412:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/5/202414:02PRNCATakeda Canada Inc. conclut une lettre d'intention avec..
14/5/202414:00BWTakeda to Present Oncology Portfolio and Pipeline Data at..
10/5/202413:03BWTakeda annonce ses résultats pour l’exercice 2023 et ses..
09/5/202423:07BWTakeda veröffentlicht Ergebnisse für das Geschäftsjahr 2023,..
09/5/202408:07BWTakeda Announces FY2023 Full Year Results and FY2024..
26/4/202414:30BWTakeda Receives Positive CHMP Opinion for Fruquintinib in..
23/4/202413:00PRNUSNeurocrine Biosciences Reports Positive Phase 2 Data for..
22/4/202410:10PRNUSTakeda, Astellas and Sumitomo Mitsui Banking Announce Master..
19/4/202401:00BWU.S. FDA Approves Subcutaneous Administration of Takeda’s..
08/4/202414:00BWTakeda Announces New U.S. Corporate Social Responsibility..
27/3/202413:56PRNUSEmpathy in Action: Takeda's Global Initiative Brings IBD..
27/3/202413:53PRNUSEmpathy in Action: Takeda's Global Initiative Brings IBD..
27/3/202406:01BWTakeda gibt Kandidaten für den Vorstand bei der kommenden..
27/3/202400:07BWTakeda Announces Candidates for Board of Directors at..
26/3/202413:00BWTakeda Announces Approval of ADZYNMA® Intravenous Injection..
21/3/202414:39BW武田薬品、Ph+..
21/3/202408:33BWTakeda meldet sNDA-Zulassung von ICLUSIG® (Ponatinib) durch..
20/3/202420:18BWTakeda annonce l'approbation par la FDA des États-Unis d'une..
19/3/202417:20BWTakeda Announces U.S. FDA Approval of Supplemental New Drug..
19/3/202411:30GLOBECENTOGENE Extends Strategic Partnership With Takeda to..
13/3/202413:00BWTakeda Announces Positive Topline Results from Phase 2 Study..
28/2/202413:03BW武田薬品とBiological E. Limited、デング熱流行地域におけるワクチンへのアクセス促進で協力
27/2/202423:26BWTakeda et Biological E. Limited s’associent pour accélérer..
27/2/202413:38BWTakeda und Biological E. Limited arbeiten zusammen, um den..
27/2/202405:30BWTakeda and Biological E. Limited Collaborate to Accelerate..
26/2/202413:00PRNCAFaire entendre sa voix à l'occasion de la Journée des..
12/2/202414:00BWFDA Approves Takeda’s EOHILIA (budesonide oral suspension),..
09/2/202400:00BWTakeda Intends to Rapidly Initiate the First Global Phase 3..
01/2/202422:23BWTakeda gibt Nachfolger für die Position des Chief Financial..
01/2/202422:18BWTakeda annonce la succession de son directeur financier
01/2/202415:59BWTakeda annonce ses résultats pour le troisième trimestre de..
01/2/202412:18EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/2/202412:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/2/202407:54BWTakeda Announces Chief Financial Officer Succession
01/2/202407:02BWTakeda Announces Third-Quarter FY2023 Results; On-Track..
30/1/202417:00BW武田薬品、慢性炎症性脱髄性多発根神経炎(CIDP)に対する維持療法としてのHYQVIA®について、欧州委員会から承認を獲得
30/1/202414:04BWTakeda-Arzneimittel HYQVIA ® von der Europäischen Kommission..
29/1/202419:55BWLe HYQVIA® de Takeda approuvé par la Commission européenne..
29/1/202417:10BWTakeda’s GAMMAGARD LIQUID® Approved by U.S. FDA for Adults..
29/1/202408:00BWTakeda’s HYQVIA® Approved by European Commission as..
25/1/202423:00PRNUSCognizant Helping to Modernize Infrastructure and..
25/1/202412:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/1/202412:11EDGAR2Form SC 13D/A - General statement of acquisition of..
19/1/202412:03EDGAR2Form SC 13G - Statement of acquisition of beneficial..

Dernières Valeurs Consultées

Delayed Upgrade Clock